← Back to Search
Drug-related Cardiotoxicity For The Treatment Of Haematological Malignancies In Elderly.
A. Malato, G. Saccullo, G. Fazio, B. Vergara, S. Raso, G. Guarneri, A. Russo, V. Abbadessa, S. Siragusa
Published 2010 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Several publications have focused on the cardiotoxicity of specific classes of hematological therapeutic agents such as antracyclines and cyclofosfamide. Cardiotoxicity of cancer chemotherapeutics is a problem for patients of all ages, but it increases with age. Toxicity can also develop months after the last chemotherapy dose, and late reactions can be seen years later when they present as new-onset cardiomyopathy. No data are available about the cardiotoxicity of non-chemotherapy agents currently used as preferred therapy for hematological malignancy in elderly. In this review we have provided a summary of the cardiovascular toxic effects produced by different drugs and therapeutic agents. Early identification of patients who are at risk for cardiotoxicity should be a primary goal for hematologists in the development of personalized antineoplastic therapeutic strategies or interventions. Thus, the discovery of new biomarkers to identify patients at a high risk for the development of these complications is a high priority. Although targeted therapies such as imatinib and anti-CD20 antibody such rituximab are considered less toxic and better tolerated by patients compared with classic chemotherapy drugs, certain cardiological complications can be very serious and as these agents have been in use for a limited period of time.
This paper references
[Thalidomide-associated bradycardia in patients with hematologic diseases: a single institution experience].
Irene López-de la Cruz (2006)
Adriamycin. A new anticancer drug with significant clinical activity.
R. Blum (1974)
Cardiotoxicity associated with high-dose cyclophosphamide therapy.
J. Gottdiener (1981)
Long-term cardiac toxicity after adjuvant epirubicinbased chemotherapy in early breast cancer: French Adjuvant StudyGroup results
P. Fumoleau (2006)
Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma
S. Kilickap (2008)
Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
J. Bajpai (2008)
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.
S. Limat (2003)
Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.
J. He (2001)
Bradycardia during therapy for multiple myeloma with thalidomide.
I. Fahdi (2004)
Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study
L. Gullestad (2005)
Practical management of dasatinib for maximum patient benefit.
I. Galinsky (2009)
Cardiotoxicity induced by tyrosine kinase inhibitors
George S Orphanos (2009)
Long‐term follow‐up of patients with intermediate or high‐grade non‐Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone
F. Rossini (2004)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
J. Foran (2000)
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Y. Will (2008)
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
P. Schein (1976)
Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
D. Hershman (2008)
Apoptosis contributes to cyclophosphamide-induced cardiomyopathy
JT Beranek (2002)
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Y. Park (2006)
Predicting Cancer Therapy-Induced Cardiotoxicity
J. Sparano (2002)
Cancer therapyrelated cardiotoxicities
S Tisma Dupanovic (2005)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A. Dispenzieri (2003)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkelä (2006)
Barriers to follow‐up care of survivors in the United States and the United Kingdom
K. Oeffinger (2006)
Risk factors for doxorubicininduced congestive heart failure
DD Von Hoff (1979)
Congestive heart failure in patients treated with doxorubicin : a retrospective analysis of three tri
SM Swain (2003)
Cardiac safety of liposomal anthracyclines.
M. Ewer (2004)
Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
Z. Hu (2009)
Effect of anthracycline antibiotics on oxygen radical formation in rat heart.
J. Doroshow (1983)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).
G. Palladini (2005)
The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity
J. Kwok (2000)
Cardiotoxicity of Cancer Chemotherapy
Valeriano C. Simbre (2005)
Phase II evaluation of adriamycin in human neoplasia
R. O'bryan (1973)
Combination chemoimmunotherapy of metastatic breast cancer with 5‐fluorouracil, adriamycin, cyclophosphamide, and BCG
G. Hortobagyi (1979)
Models of care for survivors of childhood cancer
D. Friedman (2006)
Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma
Y. Arai (2005)
The use of cyclophosphamide for clinical marrow transplantation.
G. Santos (1972)
Importance of clinical and epidemiological research in defining the long‐term clinical care of pediatric cancer survivors
M. Hawkins (2006)
N-acetylcysteine prevents the doxorubicin-induced decrease of cyclic GMP.
D. Unverferth (1983)
In vivo prevention of cyclophosphamide-induced Ca2+ dependent damage of rat heart and liver mitochondria by cyclosporin A.
I. Al-Nasser (1998)
Rituximab-induced polymorphic ventricular tachycardia.
Joseph T. Poterucha (2010)
Combination chemotherapy of advanced Hodgkin's disease.
J. L. Gray (1973)
Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma
José Manuel Cervera Grau (2008)
The proteasome: a novel target for anticancer therapy
C. Montagut (2006)
Haemopoietic stem-cell transplantation: recent progress and future promise.
C. Craddock (2000)
Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
S. Zver (2008)
An evaluation of the cardiotoxicity of imatinib mesylate.
A. Ribeiro (2008)
Unexpected cardiotoxicity in haematological bortezomib treated patients.
Orciuolo Enrico (2007)
Amputation and adriamycin in primary osteosarcoma.
E. Cortés (1974)
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer.
A. Martoni (1990)
Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma
S. Shah (2012)
Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia.
J. Horacek (2008)
Late effects after treatment of childhood cancer
IA Alvarez (2007)
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.
S. Hunt (2002)
Anthracycline cardiomyopathy monitored by morphologic changes.
M. Billingham (1978)
Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
V. Pai (2000)
IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma
D. Maloney (1997)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
B. E. C. Oiffier (2002)
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
D. Seldin (2003)
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
M. Cohen (2002)
Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients
J. Robert (1992)
Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
E. C. van Dalen (2010)
Neuro - hormones and cytokines in heart failure . Correlation with coronary flow reserve
I Coma-Canella (2002)
Pathology of radiation and anthracycline cardiotoxicity
G. Berry (2005)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
G. Batist (2001)
SequentialAdriamycin- Ara-C (A-OAP) for remission induction (RI) of adult acute leukemia (AAL)
KB McCredie (1976)
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
F. Zaja (2010)
Trends in prevalence and outcome of heart failure with preserved ejection fraction.
Theophilus E Owan (2006)
Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
A. Braverman (1991)
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
W. Peters (1993)
Delivering long‐term follow‐up care to pediatric cancer survivors: Transitional care issues
J. Ginsberg (2006)
Nilotinib therapy in chronic myelogenous leukemia.
A. Quintás-Cardama (2007)
Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis
M. Lacy (2010)
Cyclophosphamide cardiac injury mimicking acute myocardial infarction.
E. Dow (1993)
Chronic myeloid leukaemia.
R. Hehlmann (2007)
Tumor Angiogenesis: Insights and Innovations
Fernando Nussenbaum (2010)
Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis
M. I. Gharib (2002)
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.
M. Goldberg (1986)
Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma
H. Takamatsu (2010)
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
E. Barry (2007)
Clinical significance of cyclophosphamide-induced cardiotoxicity.
I. Taniguchi (2005)
Cardiotoxicity caused by chemotherapy
A. S. Hinkle (2003)
This paper is referenced by
Reversal of cardiomyopathy with tocilizumab in a case of HIV‐negative Castleman's disease
L. Man (2013)
Putative Mechanisms Underlying Cardiovascular Disease Associated with Clonal Hematopoiesis of Indeterminate Potential
Sarah S. Burns (2020)
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib
S. K. gülsaran (2019)